drugset / Trial / NCT00000221

Alternate-Day Buprenorphine Administration. Phase I - 3

NCT00000221

CrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.

Timeline

Start
1992-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified